- Home
- CRL
as 12-24-2024 4:00pm EST
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
| Founded: | 1947 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 9.8B | IPO Year: | 2000 |
| Target Price: | $211.64 | AVG Volume (30 days): | 531.0K |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.00 | EPS Growth: | -13.25 |
| 52 Week Low/High: | $176.48 - $275.00 | Next Earning Date: | 02-12-2025 |
| Revenue: | $4,060,916,000 | Revenue Growth: | -3.67% |
| Revenue Growth (this year): | -1.39% | Revenue Growth (next year): | 1.18% |
Stock Insider Trading Activity of Charles River Laboratories International Inc. (CRL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WALLMAN RICHARD F | CRL | Director | Nov 6 '24 | Sell | $216.25 | 7,621 | $1,647,418.25 | 15,636 |
Latest Charles River Laboratories International Inc. News
CRL Breaking Stock News: Dive into CRL Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects
MT Newswires
7 days ago
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $245 From $250
MT Newswires
8 days ago
Morgan Stanley Trims Price Target on Charles River Laboratories International to $220 From $225, Keeps Equalweight Rating
Zacks
19 days ago
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
Zacks
19 days ago
CRL Stock to Gain From the Global Biotech Incubator Program Launch
Business Wire
20 days ago
Charles River Introduces Global Biotech Incubator Program
Business Wire
23 days ago
Charles River Laboratories to Present at Evercore ISI Investor Conference
Simply Wall St.
a month ago
At US$200, Is It Time To Put Charles River Laboratories International, Inc. (NYSE:CRL) On Your Watch List?
Compare CRL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRL Charles River Laboratories International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.